Abstract:Background: The TP53 tumor suppressor gene plays an important role in preventing and inhibiting the growth of tumor by regulating cell cycle, apoptosis and DNA repair. Meanwhile, the TP53 gene is one of the most frequently altered gene in non-small cell lung cancer (NSCLC) patients. Mutant TP53 (TP53-MUT) may lose tumor suppressor activity and gain tumor promoting functions, which play an important role in cancer risk, therapy resistance and poor prognosis. The impact of TP53-MUT on the prognosis of NSCLC patients need to be further studied.Methods: We obtained genomic and clinical data from The Cancer Genome Atlas (TCGA). Mutation profiles, the TMB, disease-free survival (DFS), and overall survival (OS) were compared between patients with different TP53-MUT statuses.Results: TP53-MUTs were detected in 46.6% of patients with lung adenocarcinoma (LUAD) (264 of 566) and 82.3% of those with lung squamous cell carcinoma (LUSC) (401 of 487). The most frequently co-mutated genes in patients with LUAD carrying a TP53-MUT included classic driver genes such as epidermal growth factor receptor (EGFR) and anaplastic large-cell lymphoma kinase (ALK), while Kirsten rat sarcoma viral oncogene (KRAS) mutations and TP53-MUTs appear to be mutually exclusive. This mutual exclusivity was not observed in patients with LUSC, in whom titin (TTN) and CUB and Sushi multiple domains 3 (CSMD3) were the most frequently co-mutated genes. A higher TMB was significantly associated with TP53-MUTs in patients with LUAD but not in those with LUSC. In patients with stage I-III NSCLC who had undergone surgery, there was no significant difference in DFS between patients carrying TP53-wildtype (TP53-WT) and TP53-MUTs, irrespective of histology or mutation type. However, the presence of TP53-MUT was associated with shorter OS in patients with LUAD (49 vs. 54 months, respectively; P=0.13) and significantly longer OS in those with LUSC (62 vs. 29 months, respectively; P=0.015).Conclusions: In contrast to most previous studies, we revealed TP53-MUT characteristic in NSCLC patients according to histology-specific differences and the association between TP53-MUT and the mutation landscape, the TMB, and the OS. These findings suggest a need for individualized management for patients with LUAD and LUSC who carry a TP53-MUT, and warrant further research.

Mutant TP53 promotes invasion of lung cancer cells by regulating desmoglein 3

Mutant p53 in cancer: from molecular mechanism to therapeutic modulation

Mutant p53 in Cancer Progression and Targeted Therapies

TP53 Mutations Upregulate RCP Expression Via Sp1/3 to Drive Lung Cancer Progression

Abstract LT06: Understanding the Role of Mutant TP53 in Lung Cancer Using Novel Genetically Engineered Mouse Models

Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway

Unraveling the Role of TP53 in Colorectal Cancer Therapy: From Wild-Type Regulation to Mutant

TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress

A protumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinoma

Regulated secretion of mutant p53 negatively affects T lymphocytes in the tumor microenvironment

Should mutant TP53 be targeted for cancer therapy?

TP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications

Genomic landscape and prognosis of patients with TP53-mutated non-small cell lung cancer

Deficient or R273H and R248W Mutations of p53 Promote Chemoresistance to 5-FU <i>via</i> TCF21/CD44 Axis-Mediated Enhanced Stemness in Colorectal Carcinoma

Mutant p53 achieves function by regulating EGR1 to induce epithelial mesenchymal transition

The Development of P53-Targeted Therapies for Human Cancers

Mutant P53 in the formation and progression of the tumor microenvironment: Friend or foe

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation

Mutant TP53 G245C and R273H Promote Cellular Malignancy in Esophageal Squamous Cell Carcinoma

Mutant p53 Gain of Function and Chemoresistance: The Role of Mutant p53 in Response to Clinical Chemotherapy